Skip to main content

WATSON 3209 Pill - yellow capsule/oblong, 18mm

Pill with imprint WATSON 3209 is Yellow, Capsule/Oblong and has been identified as Rivastigmine Tartrate 3 mg. It is supplied by Watson Pharmaceuticals.

Rivastigmine is used in the treatment of Alzheimer's Disease; Parkinson's Disease and belongs to the drug class cholinesterase inhibitors. There is no proven risk in humans during pregnancy. Rivastigmine 3 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for WATSON 3209

Rivastigmine tartrate 3 mg WATSON 3209
Rivastigmine tartrate 3 mg WATSON 3209

Rivastigmine Tartrate

Imprint
WATSON 3209
Strength
3 mg
Color
Yellow
Size
18.00 mm
Shape
Capsule/Oblong
Availability
Prescription only
Drug Class
Cholinesterase inhibitors
Pregnancy Category
B - No proven risk in humans
CSA Schedule
Not a controlled drug
Labeler / Supplier
Watson Pharmaceuticals
Inactive Ingredients
silicon dioxide, magnesium stearate, microcrystalline cellulose, gelatin, titanium dioxide, ferric oxide yellow, D&C Yellow No. 10, FD&C Blue No. 1, FD&C Blue No. 2, indigotindisulfonate sodium, FD&C Red No. 40, shellac, propylene glycol

Note: Inactive ingredients may vary.

Labelers / Repackagers

NDC Code Labeler / Repackager
00591-3209 (Discontinued) Watson Pharmaceuticals, Inc.
63739-0577 (Discontinued) McKesson Packaging Services

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.